BioNexus Gene Lab Corp Files 8-K
Ticker: BGLC · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1737523
| Field | Detail |
|---|---|
| Company | Bionexus Gene Lab CORP (BGLC) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $450,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, medical-laboratories
TL;DR
BioNexus Gene Lab Corp filed an 8-K on 9/12 for an event on 9/11.
AI Summary
BioNexus Gene Lab Corp. filed an 8-K on September 12, 2024, reporting an event on September 11, 2024. The filing is categorized under Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Wyoming, operates in the Medical Laboratories sector.
Why It Matters
This 8-K filing indicates a significant event or update from BioNexus Gene Lab Corp. that requires public disclosure to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K disclosure without immediate indication of significant financial distress or major corporate changes.
Key Numbers
- 001-41750 — SEC File Number (Identifies the company's filing with the SEC.)
- 35-2604830 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- BioNexus Gene Lab Corp. (company) — Registrant
- Wyoming (jurisdiction) — State of incorporation
- September 12, 2024 (date) — Filing date
- September 11, 2024 (date) — Date of earliest event reported
FAQ
What specific event triggered this 8-K filing?
The filing does not specify the exact event, only that it was reported on September 11, 2024, and is categorized under Regulation FD Disclosure and Financial Statements and Exhibits.
When was BioNexus Gene Lab Corp. incorporated?
The company was incorporated in Wyoming.
What is the primary business of BioNexus Gene Lab Corp.?
The company's Standard Industrial Classification is SERVICES-MEDICAL LABORATORIES [8071].
What is the company's SEC file number?
The SEC file number for BioNexus Gene Lab Corp. is 001-41750.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 678 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-09-12 15:01:40
Key Financial Figures
- $450,000 — has invested RM 2 million (approx. USD $450,000) to commence production of fine-quality
Filing Documents
- bglc_8k.htm (8-K) — 28KB
- bglc_ex991.htm (EX-99.1) — 13KB
- bglc_ex992.htm (EX-99.2) — 9KB
- 0001477932-24-005680.txt ( ) — 181KB
- bglc-20240911.xsd (EX-101.SCH) — 6KB
- bglc-20240911_lab.xml (EX-101.LAB) — 15KB
- bglc-20240911_cal.xml (EX-101.CAL) — 1KB
- bglc-20240911_pre.xml (EX-101.PRE) — 9KB
- bglc-20240911_def.xml (EX-101.DEF) — 2KB
- bglc_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On September 11, 2024, BioNexus Gene Lab Corp (the "Company") issued a press release announcing that its subsidiary, Chemrex Corporation Sdn Bhd., a Malaysian corporation and a wholly owned subsidiary of the Company ("Chemrex"), has invested RM 2 million (approx. USD $450,000) to commence production of fine-quality color paste (non-drying type) for composite industrial customers, with operations set to begin in September 2024. The press release outlines the advantages of this new production line, including increased profit margins, improved quality control, timely delivery of products, competitive pricing, and market opportunities in Southeast Asia, the Middle East, Australia, and New Zealand. The press release also highlights future expansion plans for the establishment of additional production facilities in the Middle East and Vietnam, as well as synergies created through bulk purchasing of raw materials to enhance cost efficiency and expand into new industries. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On September 12, 2024, the Company issued a press release announcing that that its wholly owned subsidiary MRNA Scientific Sdn. Bhd. ("MRNA Scientific") has signed a strategic partnership Memorandum of Understanding with Shenzhen Rongguang Health Group, a leading healthcare provider in China. The collaboration aims to expand expertise in cancer screening, precision medicine, and preventative healthcare, focusing on early detection, personalized health solutions, and chronic disease management. Through MRNA Scientific, the Company will enhance cancer screening across Southeast Asia and China, while both companies will jointly develop regenerative medicine technologies and preventative care solutions. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K. 2
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 99.1 Press Release Dated September 11, 2024. 99.2 Press Release Dated September 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. Date: September 12, 2024 By: /s/ Su-Leng Tan Lee Name: Su-Leng Tan Lee Title: Chief Executive Officer 4